Company & Sponsor Intelligence

Orion Corporation, Orion Pharma

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials3

Recruiting0

Completed2

Countries1

Therapeutic footprint

alzheimersparkinsons

Indexed studies

NCT00562198PET-Study: Effects of Single Doses of Stalevo and Levodopa/Carbidopa on Striatal 11C-Raclopride Binding
parkinsons · FinlandPHASE2

NCT02764125Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC)
parkinsons · FinlandPHASE2

NCT01324518Safety and Efficacy of ORM-12741 in Patients With Alzheimer's Disease
alzheimers · FinlandPHASE2

Intelligence layer updated: 2026-10-29 06:17:44.639239+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →